Print
|
Close
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Active:
No
Cancer Type:
Bone Tumor
NCT ID:
NCT04100018
Trial Phases:
Phase III
Protocol IDs:
CA209-7DX (primary)
NCI-2019-08322
2019-002030-36
Eligibility:
18 Years and older, Male
Study Type:
Treatment
Study Sponsor:
Bristol-Myers Squibb
NCI Full Details:
http://clinicaltrials.gov/show/NCT04100018
Summary
The purpose of this study is to assess the safety and effectiveness of nivolumab with
docetaxel in men with advanced castration resistant prostate cancer who have progressed
after second-generation hormonal manipulation.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.